Please assess the completion status of the following clinical trial:

Trial Title: Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Men and women at least 18 years old with evidence or a history of atherosclerosis involving the coronary, cerebral, or peripheral vascular systems by one or more of the following:~* history of myocardial infarction (heart attack)~* history of ischemic stroke (stroke due to a blocked artery)~* history of peripheral arterial disease~Exclusion Criteria:~* history of intracranial hemorrhage or of central nervous system (CNS) surgery, tumor, or aneurysm~* any bleeding disorder or abnormality~* sustained severe hypertension or valvular heart disease~* current or recent platelet count \<100,000 mm\^3~* planned or ongoing treatment with a blood thinning medication~* pregnancy~* any significant medical or physiological condition or abnormality that could put the subject at increased risk or limit the subject's ability to participate for the duration of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): 1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.
- Vorapaxar (Type: EXPERIMENTAL): one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.

Based on this trial design, predict the completion outcome and termination type (if applicable).